61350-00-3

Basic information

• Product Name: VU 0364770
• Synonyms: VU 0364770;2-PyridinecarboxaMide, N-(3-chlorophenyl)-;N-(3-chlorophenyl)pyridine-2-carboxamide;N-(3-Chlorophenyl)picolinamide
• CAS NO: 61350-00-3
• Molecular Formula: C₁₂H₉ClN₂O
• Molecular Weight: 232.66566
• Product Categories: Aromatics, Heterocycles;Inhibitors
• Mol File: 61350-00-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 81-83 °C
• Boiling Point: 293.6±20.0 °C(Predicted)
• Appearance: /
• Density: 1.341±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 11.24±0.70(Predicted)
• CAS DataBase Reference: VU 0364770(CAS DataBase Reference)
• NIST Chemistry Reference: VU 0364770(61350-00-3)
• EPA Substance Registry System: VU 0364770(61350-00-3)

Safety Data

• Hazardous Substances Data: 61350-00-3(Hazardous Substances Data)

Usage

Description

VU 0364770, also known as N-(3-Chlorophenyl)-2-pyridinecarboxamide, is a compound that demonstrates positive allosteric modulation at the mGlu4 receptors. This modulation occurs in combination with other antagonists and has potential applications in the treatment of neurodegenerative diseases.

Uses

Used in Pharmaceutical Industry:
VU 0364770 is used as a therapeutic agent for the treatment of neurodegenerative Parkinson's disease. Its positive allosteric modulation at the mGlu4 receptors, in combination with other antagonists, helps in managing the symptoms and progression of the disease.
Used in Research and Development:
VU 0364770 is also used in research and development for understanding the role of mGlu4 receptors in neurodegenerative diseases and exploring potential therapeutic strategies. Its modulation properties make it a valuable tool in studying the underlying mechanisms and pathways involved in Parkinson's disease and other related conditions.

Upstream product

• 98-98-6 2-Picolinic acid 
• 108-42-9 3-chloro-aniline 
• 39901-94-5 2-picolinoyl chloride hydrochloride 
• 29745-44-6 pyridine-2-carbonyl chloride 

Downstream Products

• 1535179-56-6 IrCp*Cl(pyridine-2-carboxylic acid N-(3-chlorophenyl)amide) 
• 1535179-59-9 RhCp*Cl(pyridine-2-carboxylic acid N-(3-chlorophenyl)amide) 
• 1535179-62-4 Ru-p-cymene*Cl(pyridine-2-carboxylic acid N-(3-chlorophenyl)amide) 
• 445-14-7 5-chloro-2-(trifluoromethyl)aniline 
• 794581-34-3 N-(3-chloro-4-methoxyphenyl)picolinamide 
• 83753-58-6 N-(3,4-dichlorophenyl)picolinamide 

Relevant articles and documents

Copper-mediated ortho C–H primary amination of anilines

We report herein a copper-mediated ortho C–H primary amination of anilines by using cheap and commercially available benzophenone imine as the amination reagent. The protocol show good functional group tolerance and heterocyclic compatibility. Late-stage diversification of drugs demonstrate the synthetic utility of this protocol.

Rhodium(III) Dihalido Complexes: The Effect of Ligand Substitution and Halido Coordination on Increasing Cancer Cell Potency

This work presents the synthesis of eight new rhodium(III) dihalido complexes, [RhX2(L)(LH)] (where X = Cl or I), which incorporate two bidentate N-(3-halidophenyl)picolinamide ligands. The ligands have different binding modes in the complexes, whereby one is neutral and bound via N,N (LH) coordination, while the other is anionic and bound via N,O (L) coordination. The solid state and solution studies confirm multiple isomers are present when X = Cl; however, after a halide exchange with potassium iodide (X = I) the complexes exist exclusively as single stable trans isomers. NMR studies reveal the Rh(III) trans diiodido complexes remain stable in aqueous solution with no ligand exchange reported over 96 h. Chemosensitivity data against a range of cancer cell lines show two cytotoxic complexes, where L = N-(3-bromophenyl)picolinamide ligand. The results have been compared to the analogous Ru(III) complexes and overall highlight the Rh(III) trans diiodido complex to be ～78× more cytotoxic than the analogous Rh(III) dichlorido complex, unlike the Ru(III) complexes which are equitoxic against all cell lines. Additionally, the Rh(III) trans diiodido complex is more selective toward cancerous cells, with selectivity index (SI) values >25-fold higher than cisplatin against colorectal carcinoma.

Rh-Catalyzed Annulative Insertion of Terminal Olefin onto Pyridines via a C-H Activation Strategy Using Ethenesulfonyl Fluoride as Ethylene Provider

A Rh(III)-catalyzed annulative insertion of ethylene onto picolinamides was achieved, providing a portal to a class of unique pyridine-containing molecules bearing a terminal olefin moiety for diversification. Application of this method for modification of Sorafenib was also accomplished.